Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Curr Pharm Des. 2013;19(35):6330-9.

Restenosis treatments using nanoparticle-based drug delivery systems.

Author information

  • 1ARC Centre of Excellence for Functional Nanomaterials, Australian Institute of Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia. gordonxu@uq.edu.au.


Restenosis, the re-narrowing of a blood vessel after removal of atherosclerotic plaque, is a major limitation of surgical treatments for atherosclerosis. Various attempts to prevent or treat restenosis by pharmacological or mechanical approaches have had limited success in clinical trials. Hence, there is wide interest in developing new strategies to prevent or treat restenosis. This review discusses 'a new-generation therapy' that uses functional nanoparticles to effectively deliver active drug molecules. The potential platforms for nanoparticle-based solutions to restenosis include organic (e.g. polymers, liposomes, and proteins) and inorganic nanoparticles (e.g. layered double hydroxides, titanium oxide nanotubes, and magnetic nanoparticles,). Many in vitro and in vivo studies based on these platforms demonstrate the feasibility and potential of using nanoparticle drug delivery systems for preventing or treating restenosis, but as yet few have reached clinical trials. It is suggested that using inorganic nanoparticles to target deliver multi-functional drugs will be a promising approach to preventing or treating restenosis.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Write to the Help Desk